Nanocrystalline Megestrol Acetate
Phase 3Small molecule
Changchun GeneScience Pharmaceutical Co., Ltd.Nanocrystalline Megestrol Acetate is one of 164 small molecule programs targeting Cachexia. It is currently in Phase 3.
5
Indications
6
Total Trials
6
Active Trials
163
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Erbitux
IImclone
Phase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Nanocrystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Sac-TMT
Merck & Co.Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cachexia2 trials
Cervical Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details